ClinicalTrials.gg

Program

inclisiran

Also written as “Inclisiran”, “Inclisiran Sodium” and “ALN-PCSSC”.

Its studies are mostly in Hypercholesterolemia · Atherosclerosis · Homozygous Familial Hypercholesterolemia · Acute Coronary Syndrome · Hyperlipoproteinemia Type II, led by 2 companies.

Furthest: phase 4, since Dec 13, 202137 company-led studies, 15 open or runningNext primary completion: Nov 27, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis3615 open or runningphase 4since Dec 13, 2021Nov 3, 2015Nov 27, 2026phase 4 · NCT06501443
Alnylam Pharmaceuticals10 open or runningphase 1since Dec 5, 2014Dec 5, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 20 studies since Dec 5, 2014.

  1. Apr 29, 2022Phase 3 study in Coronary Artery DiseaseNovartis · NCT05360446 · 610 enrolled · United States, Argentina, Australia and more
  2. Dec 27, 2022Phase 3 study in Homozygous Familial HypercholesterolemiaNovartis · NCT05682378 · 195 planned · United States, Argentina, Brazil and more
  3. Feb 13, 20232 phase 3 studiesNovartis · NCT05739383, NCT05763875
  4. May 24, 2023Phase 3 study in AtherosclerosisNovartis · NCT05888103 · 207 enrolled · China
  5. Apr 15, 20243 phase 4 studiesNovartis · NCT06372925, NCT06386419, NCT06431763
  6. Jun 21, 2024Phase 4 study in HypercholesterolemiaNovartis · NCT06501443 · 520 planned · Argentina, Brazil
  7. Sep 11, 20242 phase 3 studiesNovartis · NCT06597019, NCT06597006
  8. Feb 3, 2025Phase 3 study in AtherosclerosisNovartis · NCT06813911 · 246 enrolled · United States, China, France and more
  9. Mar 6, 2025Phase 4 study in Coronary DiseaseNovartis · NCT06941792 · 1,590 enrolled · China
  10. Jul 31, 2025Phase 3 study in Acute Coronary SyndromeNovartis · NCT07102628 · 300 planned · Argentina, Australia, Canada and more
  11. May 20, 2026Phase 2 study in HypercholesterolemiaNovartis · NCT07610278 · 120 planned · United States
  12. May 29, 2026Phase 1 study in Inclisiran FormulationNovartis · NCT07626281 · 152 planned · United States
  13. Jun 29, 2026Phase 4 study in Acute Coronary SyndromeNovartis · NCT07684469 · 300 planned
  14. Oct 30, 2026Primary completion moved from 2027-02-28 to 2028-02-29Date moved laterphase 4 · +12 months · NCT07684469

Ahead

  1. Nov 27, 2026Primary completion: phase 4 study in HypercholesterolemiaNovartis · NCT06501443
  2. Dec 21, 2026Primary completion: phase 1 study in Inclisiran FormulationNovartis · NCT07626281
  3. Dec 30, 2026Primary completion: phase 4 study in Plaque, AtheroscleroticNovartis · NCT06372925
  4. Feb 11, 2027Primary completion: phase 3 study in Acute Coronary SyndromeNovartis · NCT07102628

TargetBeta

PCSK9 →read by rule
“The present clinical trial adopted inclisiran, a PCSK9 inhibitor with well-documented clinical safety and robust lipid-lowering effects, in combination with amlodipine besylate.”study text, by rule · the study

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
alirocumabruleSanofiphase 448
evolocumabruleAmgenphase 445
lerodalcibeprulelib-therapeutics-llcphase 314
tafolecimabruleInnovent Biologicsphase 38
recaticimabruleJiangsu HengRui Medicinephase 37
QLC7401ruleQilu Pharmaceuticalphase 35
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
VERVE-102Eli Lillyphase 22
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

All 37 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07684469Acute Coronary Syndrome4Not yet recruitingNovartisFeb 29, 2028300
NCT07626281Inclisiran Formulation · United States1RecruitingNovartisDec 21, 2026152
NCT07610278Hypercholesterolemia · United States2RecruitingNovartisApr 28, 2027120
NCT07102628Acute Coronary Syndrome · Argentina, Australia, Canada and more3RecruitingNovartisFeb 11, 2027300
NCT06941792Coronary Disease · China4Active, not recruitingNovartisApr 30, 20271,590
NCT06813911Atherosclerosis · United States, China, France and more3Active, not recruitingNovartisFeb 3, 2028246
NCT06597019Hyperlipoproteinemia Type II · United States, Argentina, Austria and more3RecruitingNovartisMar 21, 202860
NCT06597006Homozygous Familial Hypercholesterolemia · United States, Austria, China and more3RecruitingNovartisMar 21, 20289
NCT06501443Hypercholesterolemia · Argentina, Brazil4RecruitingNovartisNov 27, 2026520
NCT06431763Hypercholesterolemia · Germany4CompletedNovartisDec 1, 2025402
NCT06386419Primary Hypercholesterolemia · India4CompletedNovartisJan 13, 202665
NCT06372925Plaque, Atherosclerotic · China4Active, not recruitingNovartisDec 30, 2026318
NCT05888103Atherosclerosis · China3CompletedNovartisApr 2, 2024207
NCT05763875Hypercholesterolemia · United States, Colombia, Germany and more3CompletedNovartisJun 20, 2024350
NCT05739383Cardiovascular Diseases · United States, Argentina, Australia and more3Active, not recruitingNovartisApr 16, 202914,012
NCT05682378Homozygous Familial Hypercholesterolemia · United States, Argentina, Brazil and more3RecruitingNovartisMar 25, 2032195
NCT05360446Coronary Artery Disease · United States, Argentina, Australia and more3Active, not recruitingNovartisOct 26, 2026610
NCT05192941Hypercholesterolemia · Bulgaria, Czechia, Estonia and more4CompletedNovartisJun 11, 20241,770
NCT05030428Atherosclerosis · United States, Argentina, Australia and more3Active, not recruitingNovartisMay 10, 202717,004
NCT04929249Atherosclerosis · United States3CompletedNovartisSep 15, 2023450
NCT04873934Acute Coronary Syndrome · United States3CompletedNovartisAug 7, 2024400
NCT04807400Atherosclerosis · United Kingdom3CompletedNovartisJan 13, 2023892
NCT04774003Hyperlipidemias · China1CompletedNovartisOct 18, 202140
NCT04765657Hypercholesterolemia · China, Singapore, South Korea and more3Active, not recruitingNovartisJun 9, 2022345
NCT04666298Hypercholesterolemia · Japan2CompletedNovartisApr 18, 2022312
NCT04659863Homozygous Familial Hypercholesterolemia · United States, Canada, France and more3CompletedNovartisOct 30, 202313
NCT04652726Familial Hypercholesterolemia - Heterozygous · United States, Argentina, Brazil and more3CompletedNovartisNov 9, 2023141
NCT03851705Homozygous Familial Hypercholesterolemia · Hong Kong, Israel, Russian Federation and more3CompletedNovartisMar 2, 202056
NCT03814187Hypercholesterolemia · United States, Canada, Czechia and more3CompletedNovartisFeb 13, 20233,275
NCT03400800Hypercholesterolemia · Czechia, Germany, Hungary and more3CompletedNovartisJul 31, 20191,617
NCT03399370Hypercholesterolemia · United States3CompletedNovartisSep 10, 20191,561
NCT03397121Hypercholesterolemia · United States, Canada, Czechia and more3CompletedNovartisAug 27, 2019482
NCT03159416Renal Insufficiency · New Zealand1CompletedNovartisMar 24, 201831
NCT03060577Atherosclerosis · United States, Canada, Germany and more2CompletedNovartisDec 17, 2021382
NCT02963311Homozygous Familial Hypercholesterolemia · United States, Netherlands, South Africa2CompletedNovartisOct 8, 20189
NCT02597127Atherosclerosis · United States, Canada, Germany and more2CompletedNovartisJun 7, 2017501
NCT02314442Hypercholesterolemia · United Kingdom1CompletedAlnylam PharmaceuticalsMay 201570

How it is read

Names in the registry

  • “Inclisiran”, 16 entries
  • “Inclisiran Sodium”, 4 entries
  • “inclisiran”, 3 entries
  • “ALN-PCSSC”, 3 entries
  • “Inclisiran sodium 300 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.